FDA Approves New Alzheimer's Drug
Summary from the AllSides News Team
On Tuesday, the Food and Drug Administration (FDA) approved a new drug for the treatment of Alzheimer's disease.
Key Details: In a press release, the FDA announced its approval of the Kisunla injection for the treatment of Alzheimer’s. The drug, manufactured by Eli Lilly, is a once-monthly injection intended for adults with early signs of Alzheimer's, and has been found to slow the progression of the disease by about a third. It targets proteins in the brain known as amyloid plaques, characteristic features of Alzheimer's.
Key Quote: “This is real progress. Today’s approval allows people more options and greater opportunity to have more time,” said Joanne Pike, president and CEO of the Alzheimer’s Association. “Having multiple treatment options is the kind of advancement we’ve all been waiting for — all of us who have been touched, even blindsided, by this difficult and devastating disease.”
For Context: Kisunla is the second drug of its kind to achieve FDA approval. The first drug approved to treat Alzheimer's last year was Leqembi, manufactured by Eisai and Biogen.
How the Media Covered it: Fox News (Right bias) noted that their medical contributor, Dr. Marc Siegel, believes that Kisunia is "somewhat more effective" than Leqembi. AP News (Lean Left bias) noted that Kisunia's once-a-month treatment is easier for caregivers than the twice-a-month regimen for Leqembi.
Featured Coverage of this Story
From the Left
FDA approves a second Alzheimer’s drug that can modestly slow disease
U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.
The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.
The delay seen with both drugs amounts to a matter of months — about seven months, in the case of Lilly’s...
From the Center
FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
The Food and Drug Administration on Tuesday approved Eli Lilly’s Alzheimer’s drug donanemab, expanding the limited treatment options for the mind-wasting disease in the U.S.
The agency approved the treatment, which will be sold under the brand name Kisunla, for adults with early symptomatic Alzheimer’s disease, according to the company.
Nearly 7 million Americans have the condition, the fifth-leading cause of death for adults over 65, according to the Alzheimer’s Association. By 2050, that group is projected to rise to almost 13 million in the U.S.
From the Right
FDA approves new drug for Alzheimer’s disease: ‘Meaningful results’
The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease.
Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer's disease, according to a press release from the company.
Eligible patients include those with mild cognitive impairment (MCI) and those who have mild dementia with confirmed amyloid pathology.
This is the first medication to target amyloid plaques — the proteins that build up in the brains of Alzheimer’s patients, often impairing memory and cognitive function — with evidence to support stopping...
AllSides Picks
July 5th, 2024
July 3rd, 2024
More News about Healthcare from the Left, Center and Right
From the Left
From the Center
From the Right
